Table 2.

Summary Effect Estimates of the Differences in Genetic Effect Sizes (in Log₁₀ Viral Load Per Copy of the Risk Allele) Between Seroconverters and Seroprevalent Subjects, EuroCHAVI Consortium, 2006^a

	Unadjusted for No. of Viral Load Counts				Adjusted for No. of Viral Load Counts
	Fixed Effects		Random Effects		Fixed Effects		Random Effects
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Top 100 single nucleotide polymorphisms
SC vs. SP	0.092	0.074, 0.110	0.095	0.071, 0.118	0.093	0.075, 0.111	0.095	0.071, 0.119
SCr vs. SP	0.095	0.065, 0.125	0.095	0.065, 0.125	0.111	0.080, 0.142	0.111	0.080, 0.142
Chromosome 6 subset
SC vs. SP	0.153	0.129, 0.177	0.153	0.129, 0.178	0.157	0.132, 0.181	0.157	0.132, 0.183
SCr vs. SP	0.104	0.057, 0.151	0.104	0.057, 0.151	0.111	0.063, 0.159	0.111	0.063, 0.159
Genome-wide significant variants
SC vs. SP	0.232	0.145, 0.318	0.232	0.145, 0.322	0.247	0.148, 0.347	0.264	0.137, 0.391
SCr vs. SP	0.111	−0.096, 0.318	0.111	−0.096, 0.318	0.111	−0.103, 0.325	0.111	−0.103, 0.325

Abbreviations: CHAVI, Center for HIV/AIDS Vaccine Immunology; CI, confidence interval; SC, seroconverters; SCr, seroconverters used as replicating data^b; SP, seroprevalent subjects.

^a All analyses were adjusted for age, gender, and population stratification axes.

^b Excluding the seroconverters of the original discovery data (4).